Metastatik Mide Kanserinde Kapesitabin, Sisplatin, Trastuzumab Kombinasyonunu Takiben Gelişen Akut Arteryal Trombozis

Abstract

Kanser hastalarında tromboz çok sayıda nedene bağlı olarak gelişebilmektedir. Kanserhastalarında tromboz genel populasyona göre çok daha fazladır. Kemoterapi ilişkili arteryaltromoz çok nadiren rapor edilmiştir. Kanser hastalığı hiperkoagulibiteye neden olan birdurumdur. Sisplatin bu yan etkiden en çok sorumlu tutulan ajandır. Sisplatinin bu vaskuler olayınasıl tetiklediği bilinmemektedir. Endotelyal hasarlanma temel rol oynayan faktör olarakgözlenmektedir. Diğer sorumlu tutulan hipotezler plazmada sisplatinin indüklediği vonWillebrand faktör yüksekliği, pıhtılaşma kaskadının aktivasyonu, tromboksan prostosiklinhomostatik bozukluğu ve fibroblast stimulasyonudur. Bu vaka dolayısıyla kapesitabin, sisplatin,trastuzumab kombinasyonunun nadir yan etkisi sunulmuştur

Keywords

• capecitabine
• cisplatin
• trastuzumab
• arteryal trombozis

ACUTE ARTERIAL THROMBOSIS FOLLOWING CAPECITABINE, CISPLATIN, TRASTUZUMAB COMBINATION IN METASTATIC GASTRIC ADENOCARCINOMA

Abstract

The increased risk of thrombosis in patients with active cancer has multiple causes. Althoughvenous thrombosis is more common in patients with cancer than in the general population,chemotherapy-induced arterial thrombosis rarely has been reported. Patients with cancer are ina hypercoagulable state. Cisplatin seems the most responsible from this adverse event. Themechanism by which cisplatin triggers vascular events is unknown, but endothelial damageseems to play a major role. Other proposed hypotheses are cisplatin-induced elevation of plasmalevels of von Willebrand factor, alteration of clotting cascade, thrombaxane–prostacyclinhomeostatic disturbances, and stimulation of fibroblasts. Here we report a rare side effectthat became after capecitabine, cisplatin, trastuzumab combination

Keywords

• capecitabine
• cisplatin
• trastuzumab
• arterial trombosis

References

1. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742):687-97. Epub 2010 Aug 19.
2. Rishi A, Ghoshal S. Acute multiple arterial thrombosis after cisplatin in base of tongue carcinoma: Case report. Head Neck. 2012 Aug 23. doi: 10.1002/hed.23123.
3. Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, Soff G, Parameswaran R, Hassoun H.High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011 Sep 1;29(25):3466-73.
4. Proverbs-Singh T, Chiu SK, Liu Z, Seng S, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK, Galsky MD. Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. J Natl Cancer Inst. 2012 Dec 5;104(23):1837-40. doi: 10.1093/jnci/djs435. Epub 2012 Oct 23. Review.
5. Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double- blind study. Lancet Oncol 2009;10:943–949.